East Port zve na seminář: Development of Cell Therapies, CRISPR/Cas9 and Non-viral delivery

"Development of Cell Therapies”, CRISPR/Cas9 and Non-viral delivery

With the advent of the CRISPR/Cas technology and the increasing knowledge on cancer biology and regenerative mechanisms, a staggering amount of new cell therapy approaches are attempting translation to the clinic. Join the seminar, explore the full CRISPR potential and hear about the best practices to achieve optimal workflow optimization.

 

The seminar will cover these topics:

  • Cell Therapy development workflow, focusing on pointing out critical steps in the development
  • Nucleofection Technology for Non-viral gene delivery
  • Establishment of Bioassays for Cell Therapy Testing
  • Quality Control: Mycoplasma and Endotoxin detection, Cell vitality assays
  • Development of CAR-T cell therapies

The seminar will take place on Wednesday, at 10.00, May 22nd 2019 in Prague in the Institute of Organic Chemistry and Biochemistry (conference hall, 2nd level, main building) and on Thursday, at 13:00, May 23rd 2019 in Olomouc in the Institute of Molecular and Translational Medicine (ground floor)

 

The seminar is free of charge, but we require registration of each participant:

Registration (click here), 22.5.2019 Praha, Institute of Organic Chemistry and Biochemistry (UOCHB)


09.30 - 10.00 Check in
10:00 - 10:05 Welcome
10:05 - 11.20 "Development of Cell Therapies”, CRISPR/Cas9 and Non-viral delivery – Part I.
Davide Confalonieri, PhD., Lonza, Cologne
11:20 - 11:40 Coffee break
11:40 - 12:00 "Development of Cell Therapies”, CRISPR/Cas9 and Non-viral delivery – Part II.
Davide Confalonieri, PhD., Lonza, Cologne
12:00 End


Registration (click here), 23.5.2019 Olomouc, Institute of Molecular and Translational Medicine (UMTM)


12:30 - 13:00 Check in
13:00 - 13:05 Welcome
13:05 – 14:20 "Development of Cell Therapies”, CRISPR/Cas9 and Non-viral delivery – Part I.
Davide Confalonieri, PhD., Lonza, Cologne
14:20 – 14:40 Coffee break
14:40 – 15:00 "Development of Cell Therapies”, CRISPR/Cas9 and Non-viral delivery – Part II.
Davide Confalonieri, PhD., Lonza, Cologne
15:00 End

 

 
Facebook Twitter Youtube LinkedIn